Safety and Performance Evaluation of the Rapid Ring Device

June 28, 2010 updated by: RapiDx Ltd.

Single Center, Open Label, Prospective, Non-comparative, Non-randomized Study to Assess the Safety and Performance of the Rapid Ring Device (Comparative Study to Assess the Pain Reduction)

The purpose of this study is to demonstrate the safety, performance and initial efficacy of the RapiDx device.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The study will be a single center, open label, prospective, non-comparative, randomized trial and assess the safety and performance of the Rapid Ring device. In order to assess pain reduction, a comparative study will be performed and each subject will serve as his/her own control.

Clinical assessment for all 100% patients will occur at baseline. All participants will be men and women above the age of 18. The trial will be conducted at a Medical Center.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Israel
      • Tel Aviv, Israel
        • Tel-Aviv Sourasky Medical Center
        • Contact:
        • Principal Investigator:
          • Ella Naparstek, Prof.
        • Sub-Investigator:
          • Boris Tartakovsky, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject is healthy
  • Subject's age is between 18 to 70 years old
  • Subject must be capable of providing informed consent

Exclusion Criteria:

  • Clotting disorders
  • Subject has a clinically significant untreated chronic disease which may unable him/ her to participate in the study.
  • Subject is taking anti-coagulant medication
  • Non-intact finger tip (left middle/ring finger)
  • Skin disease on the subject finger
  • Abnormal blood pressure
  • Pregnant or lactating women
  • Menstrual period
  • Previous diagnosis of HIV or Hepatitis
  • Participation in other clinical investigations within previous 30 days
  • Peripheral blood vessels diseases
  • Diabetes
  • Neuropathic pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Collection of at least 2 drops (approximately 50microliter) of blood within one minute.
Time Frame: approximately 6 months
approximately 6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Reduction in pain
Time Frame: approximately 6 months
approximately 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

RapiDx Ltd.

Investigators

  • Principal Investigator: Ella Naparstek, Prof., Chairman of the Hematology Institute and the Department of Hematology and Bone Marrow Transplantation at Tel Aviv Sourasky Medical Center.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (Anticipated)

November 1, 2010

Study Completion (Anticipated)

November 1, 2010

Study Registration Dates

First Submitted

June 27, 2010

First Submitted That Met QC Criteria

June 28, 2010

First Posted (Estimate)

June 29, 2010

Study Record Updates

Last Update Posted (Estimate)

June 29, 2010

Last Update Submitted That Met QC Criteria

June 28, 2010

Last Verified

June 1, 2010

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CTIL - CL-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Rapid Ring

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe